AOTI’s TWO2 Therapy: Can Oxygen Heal Chronic Wounds Faster—and Keep Them Healed?

Chronic wounds are a silent drain on healthcare systems. They linger. They relapse. And too often, they escalate to amputations. Now, a new large-scale study suggests a different path—one that shifts care from hospital to home.

The Study: Real-World Data, Not Controlled Perfection

A newly published multicentre retrospective cohort study in the Journal of Vascular Surgery–Vascular Insights evaluated the effectiveness of TWO2 therapy. The therapy comes from AOTI Inc.

Here’s the scale:

• 3,126 patients
• Multiple wound types:
  • Diabetic foot ulcers (DFUs)
  • Venous leg ulcers (VLUs)
  • Arterial ulcers
  • Atypical wounds
• Patients had non-healing wounds for ~7 months before treatment

This isn’t ideal-case clinical trial data. It’s messy, real-world medicine.

The Headline Numbers (And They’re Hard to Ignore)

The results:

• 64.8% complete healing rate
• Average healing time: 4.2 months
• Recurrence rate: just 2.7% over ~14 months follow-up

Now compare that to typical benchmarks. Data from the US Wound Registry shows:

• DFUs: ~45% healing
• VLUs: ~57% healing

And those populations are less complex.

What Makes TWO2 Different?

At the core is Topical Wound Oxygen (TWO2) therapy. Instead of systemic treatment or invasive procedures:

• Oxygen is delivered directly to the wound site
• Delivered in a pressurized, cyclical manner
• Therapy is non-invasive
• Can be administered at home

This matters more than it sounds. Because chronic wound care often fails due to:

• Poor oxygenation
• Inconsistent treatment adherence
• Limited access to advanced care

TWO2 targets all three.

Beyond Healing: The Outcomes That Actually Matter

Healing is step one. Avoiding relapse—and worse outcomes—is step two. The study reports:

• Hospitalisation rate: 3.7%
• Amputation rate: 6.1%

Now compare that to earlier real-world data without TWO2:

• 54.1% hospitalisations
• 41.4% amputations

That’s not incremental improvement. That’s a potential shift in patient trajectory.

Why This Matters: Chronic Wounds Are a Growing Crisis

Conditions like Diabetic foot ulcers are rising globally. Driven by:

• Increasing diabetes prevalence
• Aging populations
• Limited access to specialized wound care

The downstream impact:

• Repeated hospital visits
• High treatment costs
• Loss of mobility—and independence

Any therapy that:

• Improves healing
• Reduces recurrence
• Lowers hospital burden

…has outsized impact.

The Home-Care Advantage

One overlooked angle: where treatment happens. TWO2 therapy is designed for at-home use. That unlocks:

• Better patient compliance
• Reduced hospital load
• Lower overall costs

And in healthcare, convenience often drives outcomes as much as efficacy.

Regulatory and Market Validation

This isn’t an experimental outlier. TWO2 therapy has already received regulatory clearances from:

• U.S. Food and Drug Administration
• CE Mark (Europe)
• MHRA (UK)
• Health Canada
• NMPA (China)
• TGA (Australia)

It has also received positive recommendations from:

• Germany’s G-BA
• UK’s NICE

That’s broad institutional validation—across multiple healthcare systems.

Leadership View: Clinical + Economic Case

CEO Mike Griffiths emphasized two points:

• Improved durable healing outcomes
• Strong cost-saving potential

That second point is key. Because therapies don’t scale unless they make economic sense, not just clinical sense.

The Real Question: Is This Scalable—or Situational?

Let’s stress-test it. Best-case scenario:

• TWO2 becomes standard adjunct therapy
• Home-based wound care becomes the norm
• Significant reduction in amputations globally

Risks to watch:

• Retrospective study design (not randomized)
• Dependence on patient adherence at home
• Reimbursement variability across markets

Still, the signal is strong.

Bottom Line

AOTI Inc isn’t introducing a new drug. It’s rethinking how wounds heal. If these results hold in broader adoption:

• Fewer hospital beds will be needed
• Fewer amputations will occur
• And chronic wounds may finally become… manageable

Not cured. But controlled.  And in this category, that’s a major leap.